SELLAS Life Sciences Reports Strong Liquidity & Positive Clinical Progress for SLS009, Addressing Going Concern

summarizeSummary

SELLAS Life Sciences reported a strengthened cash position, including $42.6 million from recent warrant exercises, extending its operational runway beyond 12 months. The company also announced positive Phase 2a results for SLS009 in AML, leading to FDA guidance for a first-line study and a new European collaboration.

check_boxKey Events

• Strengthened Liquidity Position

  The company reported $71.8 million in cash and cash equivalents as of December 31, 2025, further bolstered by $42.6 million in proceeds from warrant exercises received subsequent to year-end, providing sufficient capital to fund operations for at least the next twelve months.

• Positive SLS009 Phase 2a Results in AML

  The Phase 2a clinical trial for SLS009 in relapsed/refractory AML met all primary endpoints, demonstrating an overall response rate (ORR) of 33% across all cohorts and significantly extended median overall survival (mOS) to 8.9 months, surpassing historical benchmarks of ~2.4 months.

• FDA Recommends First-Line AML Study for SLS009

  Following the positive Phase 2a results, the FDA recommended advancing SLS009 into a randomized 80-patient Phase 2 clinical trial for newly diagnosed, first-line AML patients, with enrollment commencing in Q1 2026.

• New European Collaboration for SLS009

  SELLAS entered into an agreement with IMPACT-AML, a European collaborative initiative, to conduct a clinical study evaluating SLS009, expanding patient access and supporting broader participation in Europe.

auto_awesomeAnalysis

SELLAS Life Sciences Group's annual report highlights a significantly improved liquidity position, with cash and equivalents, including recent warrant exercises, projected to fund operations for over 12 months. This addresses a critical 'going concern' risk often associated with clinical-stage biopharmaceutical companies. The report also details positive Phase 2a clinical trial results for SLS009 in relapsed/refractory AML, which met all primary endpoints and received FDA guidance to advance into a first-line therapy study. This clinical progress, coupled with a new European collaboration for SLS009, represents a material advancement in the company's pipeline. While the company continues to incur net losses and faces ongoing arbitration with a partner, the strengthened financial runway and promising clinical developments are key positive takeaways for investors.